In this meta-analysis, seven studies on sPD-L1 involving 554 patients with NSCLC, six studies on PD-L1 in CTCs involving 247 patients with NSCLC, and two studies on exoPD-L1 involving 171 patients with NSCLC were included to investigate the prognostic effect of these blood markers in patients with NSCLC undergoing ICI therapy. The gene discussed is SPDL1; the disease is non-small cell lung carcinoma.